Arcellx
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 130
- Market Cap
- $3.8B
- Website
- http://www.arcellx.com
- Introduction
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Phase 1
Not yet recruiting
- Conditions
- Muscular DiseasesNeuromuscular ManifestationsAutoimmuneAutoimmune DiseasesAutoimmune Diseases of the Nervous SystemMyasthenia GravisMuscle Weakness
- Interventions
- Biological: anito-celDrug: Standard Lymphodepletion regimen
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Arcellx, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06626919
Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS
Phase 1
Recruiting
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: SPRX002Biological: ARC-T Cells
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Arcellx, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05457010
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Montefiore Einstein Cancer Center, New Rochelle, New York, United States
© Copyright 2025. All Rights Reserved by MedPath